| Company Name: |
Clearsynth Labs Limited
|
| Tel: |
+91-22-26355700 |
| Email: |
info@clearsynth.com |
| Products Intro: |
Product Name:DL-GlutaMic-d3 Acid
CAS:96927-56-9
Remarks:CS-C-00119
|
DL-GLUTAMIC-2,4,4-D3 ACID manufacturers
- DL-Glutamic acid-d3
-
- $0.00 / 1mg
-
2025-08-21
- CAS:96927-56-9
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | DL-GLUTAMIC-2,4,4-D3 ACID Basic information |
| Product Name: | DL-GLUTAMIC-2,4,4-D3 ACID | | Synonyms: | DL-GLUTAMIC-2,4,4-D3 ACID;DL-GLUTAMIC ACID (2,4,4-D3);DL-Glutamic Acid-2,2,4-D3;DL-GlutaMic-d3 Acid;2-Aminopentanedioic acid-2,4,4-d3;DL-Glutamic acid-d3;DL-GLUTAMIC-2,4,4-D3 ACID USP/EP/BP;(2R,S)-<2,4,4-(2)H3>-glutamic acid | | CAS: | 96927-56-9 | | MF: | C5H9NO4 | | MW: | 147.13 | | EINECS: | | | Product Categories: | Amino Acids 13C, 2H, 15N | | Mol File: | 96927-56-9.mol |  |
| | DL-GLUTAMIC-2,4,4-D3 ACID Chemical Properties |
| Melting point | 185 °C (dec)(lit.) | | storage temp. | -20°C Freezer, Under inert atmosphere | | solubility | DMSO (Slightly, Heated), Water (Slightly) | | form | Solid | | color | White to Off-White | | Appearance | white solid | | CAS Number Unlabeled | 617-65-2 |
| | DL-GLUTAMIC-2,4,4-D3 ACID Usage And Synthesis |
| Description | Glutamic acid together with its γ-monoamide – glutamine – makes up about a third of all free amino acids in blood plasma, its content in body proteins is 20-25 %. In the blood, glutamic acid maintains pH balance, binds excess ammonia, turning into glutamine, transports it to the site of detoxification, and serves as a reserve of amino groups. Glutamic acid acts as an excitatory neurotransmitter and agonist of all subtypes of glutamate receptors (metabotropic, kainate, NMDA and AMPA), and is also a precursor of gamma-aminobutyric acid (GABA). Glutamic acid has an immunomodulatory effect and affects many metabolic processes. | | Uses | DL-Glutamic acid-d3 is the deuterium labeled DL-Glutamic acid. DL-Glutamic acid is the conjugate acid of Glutamic acid, which acts as a fundamental metabolite. Comparing with the second phase of polymorphs α and β L-Glutamic acid, DL-Glutamic acid presents better stability[1]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:10.1177/1060028018797110 |
| | DL-GLUTAMIC-2,4,4-D3 ACID Preparation Products And Raw materials |
|